Skip to main content
    P

    Penumbra Inc (PEN)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NYSE

    $320.63
    -0.28 (-0.09%)

    Market Cap: $12.65B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Penumbra Inc (PEN) Earnings: Report Dates and Results

    Updated Oct 29, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    In the quarter ended Sep 30, 2026, Penumbra reported EPS of $1.07, below the $1.21 estimate. It beat the EPS estimate in 5 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    74%(29/39)
    Avg Surprise
    +65.72%

    Upcoming Estimates

    Report date not yet scheduledPeriod ending Dec 31, 2026
    EPS Consensus$1.44
    Range$1.10 - $1.69
    11 analysts
    Revenue Consensus
    $434.51M
    Range$406.70M - $465.22M
    12 analysts
    Report date not yet scheduledPeriod ending Mar 31, 2027
    EPS Consensus$1.40
    Range$1.33 - $1.49
    4 analysts
    EPS Revisions
    0
    1
    30d
    EPS Estimate DriftChange to current
    90d ago$1.39+0.6%
    60d ago$1.39+0.6%
    30d ago$1.39+0.6%
    7d ago$1.40-0.2%
    Current$1.40
    Revenue Consensus
    $424.57M
    Range$422.52M - $425.80M
    3 analysts

    Next Report

    Analysts' consensus for the quarter ending Dec 31, 2026 is 22.0% above the $1.18 reported for the quarter ended Dec 31, 2025.

    PEN's report for the quarter ending Dec 31, 2026 is not on the earnings calendar yet.

    PEN Earnings Call

    The latest PEN earnings call transcript on file is labeled 2025Q3.

    Read the 2025Q3 transcript

    Earnings History

    Of the 39 quarters below that had an estimate, PEN beat 29, missed 9 and matched 1. Revenue for the quarter ended Sep 30, 2026 was $410.14M, up 15.6% from $354.69M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026$1.07$1.21$1.07 - $1.29-11.57%Miss+10.3%71 up, 3 downOct 29, 2026$410.14M
    Jun 30, 2026$0.88$1.15$1.05 - $1.27-23.48%Miss+2.3%110 up, 5 downJul 30, 2026$390.05M
    Mar 31, 2026$1.01$1.06$1.00 - $1.14-4.72%Miss+21.7%102 up, 2 downMay 6, 2026$374.76M
    Dec 31, 2025$1.18$1.10$0.99 - $1.24+7.27%Beat+21.6%184 up, 1 downFeb 25, 2026$385.38M
    Sep 30, 2025$0.97$0.90$0.85 - $1.03+7.78%Beat+14.1%193 up, 14 downNov 5, 2025$354.69M
    Jun 30, 2025$0.86$0.82$0.71 - $0.90+4.88%Beat+34.4%180 up, 1 downJul 29, 2025$339.45M
    Mar 31, 2025$0.83$0.67$0.52 - $0.84+23.88%Beat+102.4%182 up, 2 downApr 23, 2025$324.14M
    Dec 31, 2024$0.97$0.89$0.80 - $1.08+8.54%Beat+27.6%182 up, 1 downFeb 18, 2025$315.52M
    Sep 30, 2024$0.85$0.69$0.50 - $0.85+23.19%Beat+26.9%171 up, 0 downOct 30, 2024$301.04M
    Jun 30, 2024$0.64$0.56$0.51 - $0.61+14.29%Beat+48.8%150 up, 0 downJul 30, 2024$299.40M
    Mar 31, 2024$0.41$0.38$0.30 - $0.61+7.89%Beat+78.3%140 up, 0 downMay 7, 2024$278.65M
    Dec 31, 2023$0.76$0.70$0.57 - $0.87+8.57%Beat+375.0%141 up, 0 downFeb 22, 2024$284.68M
    Sep 30, 2023$0.67$0.45$0.40 - $0.53+48.89%Beat+6600.0%140 up, 0 downNov 2, 2023$270.95M
    Jun 30, 2023$0.43$0.28$0.17 - $0.34+53.57%Beat+4200.0%130 up, 0 downAug 1, 2023$261.50M
    Mar 31, 2023$0.23$0.11$0.04 - $0.17+109.09%BeatN/A120 up, 0 downMay 2, 2023$241.40M
    Dec 31, 2022$0.16$0.15$0.07 - $0.23+6.67%Beat+60.0%120 up, 0 downFeb 23, 2023$221.22M
    Sep 30, 2022$0.01$0.01-$0.11 - $0.070.00%In line-91.7%110 up, 0 downNov 3, 2022$213.68M
    Jun 30, 2022$0.01-$0.03-$0.17 - $0.05+133.33%Beat-95.2%101 up, 0 downAug 4, 2022$208.34M
    Mar 31, 2022-$0.01$0.04-$0.05 - $0.21-125.00%Miss-103.7%90 up, 0 downMay 3, 2022$203.90M
    Dec 31, 2021$0.10$0.22$0.12 - $0.33-54.55%Miss-76.2%70 up, 0 downFeb 22, 2022$204.01M
    Sep 30, 2021$0.12$0.17$0.06 - $0.23-29.41%Miss+100.0%8N/ANov 3, 2021$190.12M
    Jun 30, 2021$0.21$0.17$0.09 - $0.24+23.53%BeatN/A7N/AAug 9, 2021$184.26M
    Mar 31, 2021$0.27$0.09-$0.04 - $0.21+200.00%Beat+575.0%7N/AMay 4, 2021$169.20M
    Dec 31, 2020$0.42-$0.07-$0.38 - $0.18+700.00%Beat+90.9%7N/AFeb 23, 2021$166.90M
    Sep 30, 2020$0.06-$0.08-$0.14 - $0.00+175.00%Beat-76.0%7N/AOct 28, 2020$151.08M
    Jun 30, 2020-$0.30-$0.39-$0.57 - -$0.18+23.08%Beat-211.1%6N/AAug 3, 2020$105.11M
    Mar 31, 2020$0.04$0.13$0.00 - $0.23-69.23%Miss-82.6%6N/AMay 7, 2020$137.33M
    Dec 31, 2019$0.22$0.19$0.13 - $0.23+15.79%Beat+69.2%5N/AFeb 25, 2020$145.26M
    Sep 30, 2019$0.25$0.16$0.12 - $0.21+56.25%Beat+47.1%6N/ANov 7, 2019$139.50M
    Jun 30, 2019$0.27$0.22$0.19 - $0.25+22.73%Beat+80.0%7N/AAug 6, 2019$134.20M
    Mar 31, 2019$0.23$0.11$0.05 - $0.22+109.09%Beat+283.3%6N/AMay 7, 2019$128.44M
    Dec 31, 2018$0.13$0.12$0.04 - $0.20+8.33%Beat-80.9%7N/AFeb 26, 2019$120.79M
    Sep 30, 2018$0.17$0.04-$0.04 - $0.09+325.00%Beat+1600.0%5N/ANov 5, 2018$111.81M
    Jun 30, 2018$0.15$0.03$0.02 - $0.03+400.00%BeatN/A5N/AAug 7, 2018$109.64M
    Mar 31, 2018$0.06-$0.02-$0.05 - $0.02+400.00%BeatN/A7N/AMay 8, 2018$102.70M
    Dec 31, 2017$0.68-$0.01-$0.04 - $0.01N/AN/AN/A6N/AFeb 27, 2018$96.05M
    Sep 30, 2017$0.01-$0.05-$0.10 - -$0.01+120.00%BeatN/A5N/ANov 7, 2017$83.91M
    Jun 30, 2017-$0.05-$0.03-$0.07 - $0.03-66.67%Miss-600.0%5N/AAug 8, 2017$80.59M
    Mar 31, 2017-$0.10-$0.05N/A-100.00%Miss-600.0%N/AN/AMay 9, 2017$73.21M
    Dec 31, 2016-$0.08-$0.09N/A+11.11%Beat-260.0%N/AN/AFeb 28, 2017$73.11M
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was $3.84, up 33.8% from the year before. It was -$0.09 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025$3.84+33.8%
    Dec 31, 2024$2.87+37.3%
    Dec 31, 2023$2.09+1129.4%
    Dec 31, 2022$0.17-75.7%
    Dec 31, 2021$0.70+218.2%
    Dec 31, 2020$0.22-77.3%
    Dec 31, 2019$0.97+90.2%
    Dec 31, 2018$0.51N/A
    Dec 31, 2017$0.54N/A
    Dec 31, 2016-$0.09N/A

    Earnings Calls

    The 6 most recent earnings calls are listed below; the latest, 2025Q3 for the period ended Sep 30, 2025, runs about 7,100 words across 15 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2025Q3Sep 30, 20257,09315
    2025Q2Jun 30, 20257,87817
    2025Q1Mar 31, 20258,59816
    2024Q4Dec 31, 20247,62717
    2024Q3Sep 30, 20246,04112
    2024Q2Jun 30, 20247,9849

    2025Q3 Earnings Call

    Opening remarks

    Cecilia Furlong Business Development and Investor Relations Thank you, operator, and thank you all for joining us on today's call to discuss Penumbra's earnings release for the third quarter of 2025. A copy of the press release and financial tables, which includes a GAAP to non-GAAP reconciliation, can be viewed under the Investors tab on our company website at www.penumbrainc.com. With me on today's call are Adam Elsesser, Chairman and CEO; Shruthi Narayan, President; and Maggie Yuen, Chief Financial Officer. Also joining us for the Q&A portion of the call is Jason Mills, EVP, Strategy. During the course of this conference call, the company will make forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding our financial performance, commercialization, clinical trials, regulatory status, quality, compliance and business trends. Actual results could differ materially from those stated or implied by our forward-looking statements due to certain risks and uncertainties, including those referenced in our 10-K for the year ended December 31, 2024, filed with the SEC. As a result, we caution you against placing undue reliance on these forward-looking statements, and we encourage you to review our periodic filings with the SEC, including the 10-K previously mentioned, for a more complete discussion of these factors and other risks that may affect our future results or the market price of our stock. Penumbra disclaims any duty to update or revise our forward-looking statements as a result of new information, future events, developments or otherwise. On this call, financial results for revenue and gross margin are presented on a GAAP basis, while operating expenses, operating income, and adjusted EBITDA are presented on a non-GAAP basis. The corresponding GAAP measures and a reconciliation of GAAP to non-GAAP financial measures are provided in our posted press release. Non-GAAP operating expenses and operating income exclude expenses related to the wind down of our Immersive Healthcare business in the third quarter of 2024 of $5 million and adjusted EBITDA excludes wind-down expenses, stock compensation expense, depreciation and amortization, provision for income taxes and interest income expenses. And with that, I would like to turn the call over to Adam.

    Adam Elsesser Chairman and CEO Thank you, Cecilia. Good afternoon. Thank you for joining Penumbra's Third Quarter 2025 Conference Call. In the third quarter, we generated total revenue of $354.7 million, representing underlying year-over-year growth of 17.8% on a reported basis and 16.9% on a constant currency basis. Our strong third quarter results reflect broad-based execution against our strategy and significant progress in further enhancing our competitive technological and market positioning across all franchises. Total U.S. revenue was $275 million in the third quarter, an increase of 21.5% compared to the third quarter of 2024. Total U.S.

    Frequently Asked Questions About PEN

    Did PEN beat earnings estimates last quarter?

    No. Penumbra reported EPS of $1.07 for the quarter ended Sep 30, 2026, below the $1.21 estimate by 11.57%.

    What EPS do analysts expect from PEN next quarter?

    The consensus EPS estimate for Penumbra for the quarter ending Dec 31, 2026 is $1.44 from 11 analysts, with estimates from $1.10 to $1.69.

    How often does PEN beat earnings estimates?

    Penumbra beat the EPS estimate in 5 of the last 8 quarters, with an average surprise of +1.57%.